Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Michael Cipriano
Keeping Track: Tpoxx Wins Green Light For Smallpox, Submissions Galore, And A Broader Approval For Xtandi
'It's not for every medication,' CMS administrator says, but agency continues to explore how to apply value-based pricing.
Product labels can be required to have warnings related to commonly prescribed unapproved uses with significant safety risks.
With at least 40 pending novel products, FDA seems poised to break its 2017 approval record of 46, and could even reach 60.